TrialReader


Pilot Study of TTI-0102 in Cystinosis

NCT07837726 — Phase 2, Not yet recruiting, 6 participants, Thiogenesis Therapeutics, Inc.

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT07837726
StatusNot yet recruiting
PhasePhase 2
Study typeInterventional; na, single group, masking: none, treatment
Enrollment6 (Estimated)
SponsorThiogenesis Therapeutics, Inc. (Industry)
ConditionsNephropathic Cystinosis, Cystinosis
InterventionsTTI-0102 (cysteamine-pantetheine disulfide) (Drug)
Datesstart 2026-10-01 (estimated), primary completion 2026-12-01 (estimated), completion 2027-03-01 (estimated), first posted 2026-09-23, last updated 2026-09-23

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Nephropathic Cystinosis All trials for Cystinosis All trials of TTI-0102 (cysteamine-pantetheine disulfide)

-Summary

White blood cell (WBC) cystine levels serve as the primary therapeutic target for monitoring cysteamine treatment in cystinosis, with a goal of <1.9 nmol ½ cystine/mg protein as measured 5-6 hours post-dose when treated with immediate-release formulation, Cystagon® , or 11-12 hours post-dose when treated with delayed-release formulation, Procysbi®, using UCSD granulocyte assay.

Although cysteamine dosing in cystinosis has traditionally been individualized based on WBC cystine levels, the FDA-approved Cystagon® prescribing information now includes an approximate recommended maintenance dose of 1.30 g/m²/day. When this dosing strategy is plotted against body weight, it aligns with the dosing regimen of TTI-0102 that was found effective in mitochondrial diseases, demonstrating a linear relationship between dose and weight.

The main objective of this study is to demonstrate that administration of a single dose of 60 ± 5 mg/kg/day of TTI-0102 (\~26 mg/kg cysteamine base equivalent) allows maintenance of WBC cystine at <1.9 nmol ½ cystine/mg protein over 24 hours as determined by UCSD granulocyte assay.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
TTI-0102 (cysteamine-pantetheine disulfide)ExperimentalDrug: TTI-0102 (cysteamine-pantetheine disulfide)Given once daily for 7 days
  • TTI-0102 (cysteamine-pantetheine disulfide) (Drug): TTI-0102 (cysteamine-pantetheine disulfide) - a prodrug of other FDA-approved forms of cysteamine

+Outcome measures

Primary outcomes

  • White blood cell (WBC) cystine [Comparison of baseline, Day 1-2, Day 3-4, and treatment end (Day 7)]: The primary endpoint is the change in white blood cell (WBC) cystine levels following treatment with TTI-0102. The study will evaluate whether a weight-based dose of 60 ± 5 mg/kg/day maintains WBC cystine levels below 1 nmol ½ cystine/mg protein over 24 hours.

Secondary outcomes

  • Pharmacokinetic parameter: Cmax [At specified days/timepoints during the treatment period: Day1-2, Day 3-4, Day 7]: cysteamine in plasma
  • Pharmacokinetic parameter: Tmax [At specified days/timepoints during the treatment period: Day1-2, Day 3-4, Day 7]: cysteamine in plasma
  • Pharmacokinetic parameter: AUC [At specified days/timepoints during the treatment period: Day1-2, Day 3-4, Day 7]: cysteamine in plasma
  • Pharmacodynamic biomarker: lactate in plasma [Baseline (Day 0) to treatment end (Day 7)]
  • Pharmacodynamic biomarker: pyruvate in whole blood [Baseline (Day 0) to treatment end (Day 7)]
  • Pharmacodynamic biomarker: tryptophan in plasma [Baseline (Day 0) to treatment end (Day 7)]

+Eligibility

Sex: All, ages: 18 Years to 65 Years

Inclusion Criteria:

* Adults aged 18-65 years with a confirmed diagnosis of cystinosis based on clinical features and/or genetic testing, with or without history of kidney transplantation.
* Currently treated with a stable dose of Cystagon® or Procysbi® for at least 3 months prior to enrollment.
* Body weight between 50 kg and 80 kg at screening.
* Able to attend all required study visits and comply with study procedures, including blood draws over a 24-hour period.
* Able to provide informed consent in English.
* The first 3 patients must have WBC cystine levels over the last year no more than 50% greater than the upper limit of target level

Exclusion Criteria:

* Known hypersensitivity or allergy to cysteamine, pantetheine, TTI-0102, or any excipients in the study drug.
* Clinically significant uncontrolled medical conditions (e.g., unstable cardiac, hepatic, or renal disease) that, in the investigator's judgment, would increase risk or interfere with study participation.
* Participation in another interventional clinical trial within 30 days prior to screening.
* Any condition that, in the investigator's opinion, would make the participant an unsuitable candidate (e.g., inability to comply with procedures, significant cognitive impairment, active substance use disorder).
* Any patient who is pregnant, plans to become pregnant or is unwilling to use contraceptive measures during study participation.

+Investigators

My Notes